Self-reported efficacy and safety of infliximab and adalimumab biosimilars after non-medical switch in patients with inflammatory bowel disease: results of a multicenter survey

Sarlós, Patrícia and Bikar, Alexander and Borbásné Farkas, Kornélia and Resál, Tamás and Szepes, Zoltán and Farkas, Klaudia and Nagy, Ferenc and Vincze, Áron and Miheller, Pál and Molnár, Tamás (2023) Self-reported efficacy and safety of infliximab and adalimumab biosimilars after non-medical switch in patients with inflammatory bowel disease: results of a multicenter survey. EXPERT OPINION ON BIOLOGICAL THERAPY, 23 (8). pp. 827-832. ISSN 1471-2598

Preview

Text 1.Self-reportedefficacyandsafetyofinfliximabandadalimumabbiosimilarsafternon-medicalswitchinpatientswithinflammatoryboweldiseaseresul.pdf Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (831kB) | Preview

Abstract

Few data are available on subjective disease control and perception of adverse events (AEs) during switching from original anti-TNF agents to biosimilars.Hungarian patients with inflammatory bowel disease were interviewed after a mandatory non-medical switch from an infliximab (IFX) originator to a biosimilar GP1111 or from an adalimumab (ADA) originator to a biosimilar GP2017. Drug choice was based on patient's and physician's decision. Subjective efficacy was measured using a 10-point scale, and AEs were assessed. Difference in efficacy before and after the switch was compared within and between the drugs.Seventy-three ADA and 106 IFX switching patients were interviewed. Subjective efficacy of IFX biosimilar was rated lower compared to IFX originator (8.72 ± 1.68 vs. 7.77 ± 2.34; p = 0.001). The ADA biosimilar was rated higher than its originator (9.02 ± 1.61 vs. 8.42 ± 1.93; p = 0.017). Patients receiving ADA biosimilar were more satisfied with the new treatment compared to IFX (p = 0.032). The incidence of new AEs was 85% in the ADA and 55% in the IFX group (1.79 vs. 0.93 AEs per patient, respectively, p < 0.001).Subjective efficacy of switching to a biosimilar was proven in case of ADA, while reduced efficacy was experienced with IFX biosimilar. Perception of AEs was high and varied between biosimilars.

Actions (login required)

Edit Item